EML2 is a gene linked to multiple cancers, including colon cancer, and its expression levels may serve as a prognostic indicator for disease outcomes.
The study analyzed EML2 expression via TCGA and GEO databases, finding it significantly overexpressed in colon cancer compared to normal tissue, with potential as a diagnostic biomarker (AUC = 0.738).
Higher EML2 levels were connected to worse overall survival and influenced immune cell infiltration, particularly affecting GTPase binding and specific immune cell types.